1. Home
  2. JFIN vs RCEL Comparison

JFIN vs RCEL Comparison

Compare JFIN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$6.98

Market Cap

373.1M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.46

Market Cap

114.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
RCEL
Founded
2011
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
373.1M
114.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
JFIN
RCEL
Price
$6.98
$3.46
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$11.75
AVG Volume (30 Days)
289.7K
196.2K
Earning Date
11-25-2025
11-06-2025
Dividend Yield
11.48%
N/A
EPS Growth
50.48
N/A
EPS
4.56
N/A
Revenue
$918,148,810.00
$72,401,000.00
Revenue This Year
N/A
$13.12
Revenue Next Year
N/A
$27.56
P/E Ratio
$1.53
N/A
Revenue Growth
8.99
20.59
52 Week Low
$5.78
$3.33
52 Week High
$19.23
$14.16

Technical Indicators

Market Signals
Indicator
JFIN
RCEL
Relative Strength Index (RSI) 32.65 37.63
Support Level $6.60 $3.33
Resistance Level $7.32 $3.58
Average True Range (ATR) 0.35 0.18
MACD 0.05 0.01
Stochastic Oscillator 35.50 22.31

Price Performance

Historical Comparison
JFIN
RCEL

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: